Novabay Pharmaceuticals Announces Preliminary Net Revenue For The Second Quarter Of 2024 Of $2.4M Versus Consensus Of $3.15M And For The First Half Of 2024 Of $5M, Primarily Derived From The Company's Eyecare Products

7/11/24 7:00:57 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $NBY alert in real time by email

Net revenue from the Company's eyecare products increased by 9% for both the second quarter and the first half of 2024 over the corresponding periods in 2023. NovaBay also expects 2024 net revenue from the Company's eyecare products to be approximately $10 million.

Get the next $NBY alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NBY

Date	Price Target	Rating	Analyst

More analyst ratings

$NBY
Press Releases

Fastest customizable press release news feed in the world

Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand
NovaBay urges stockholders to vote FOR all proxy proposals at the Special Meeting of Stockholders NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") announces that the largest institutional advisory firm, Institutional Shareholder Services (ISS), has recommended that NovaBay stockholders vote in favor of all of the Company's proxy proposals, specifically to authorize and approve the sale of its eyecare business (the "Asset Sale Proposal") and approve the voluntary liquidation and dissolution of the Company (the "Dissolution Proposal"). Proposal One (the Asset Sale Proposal) and Proposal Two (the Dissolution Proposal) are further described in the Definitive Proxy Statem
11/15/24 8:00:00 AM ET
$NBY
Biotechnology: Pharmaceutical Preparations
Health Care
NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results
Online Avenova® sales increase 14% for the quarter and 19% for the nine months Sales and marketing expenses declined 25% for the quarter and 18% for the nine months reflecting digital marketing optimization NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three and nine months ended September 30, 2024. "Avenova sales through the online channel for the quarter increased 14% over the prior year, while we reduced our marketing spend by 25% in the same period as we further optimized our highly efficient digital marketing programs," said Justin Hall, CEO of NovaBay. "We saw continued momentum in Avenova online sales into the current quarter. Sales through Amazon
11/7/24 4:05:00 PM ET
$NBY
Biotechnology: Pharmaceutical Preparations
Health Care
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) ("NovaBay" or the "Company") today announces that the Company has accepted a revised transaction proposal from PRN Physician Recommended Nutriceuticals, LLC ("PRN") to increase the base purchase price for the Company's eyecare business from $9.5 million to $11.5 million. The Company has entered into an amendment (the "Amendment") to its previously announced Asset Purchase Agreement, dated September 19, 2024, with PRN (the "Original PRN APA" and, as amended, the "PRN APA"). The Company's transaction with PRN remains subject to certain closing conditions, including receiving stockholder approval. "We are pleased to accept PRN's revised offer for the
11/6/24 4:05:00 PM ET
$NBY
Biotechnology: Pharmaceutical Preparations
Health Care

$NBY
Financials

Live finance-specific insights

NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three and six months ended June 30, 2024 after market close on Tuesday, August 13, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Tuesday, August 13, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and
8/1/24 6:50:00 AM ET
$NBY
Biotechnology: Pharmaceutical Preparations
Health Care
NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results
Net product sales increased 13% over the prior year driven by higher sales of Avenova®-branded products through OTC channels and branded wound care products Sales and marketing expenses declined 15% reflecting continued digital marketing optimization Ordered product sales for Avenova-branded products on Amazon.com reached new all-time records in March and April Conference call begins at 4:30 p.m. Eastern time today NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) reports financial results for the three months ended March 31, 2024 and provides a business update. "Net product sales growth of 13% versus the prior year was driven by higher sales of Avenova-branded products through online
5/9/24 4:05:00 PM ET
$NBY
Biotechnology: Pharmaceutical Preparations
Health Care
NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time. Date/Time: Thursday, May 9, 4:30 p.m. ET / 1:30 p.m. PT Pre-Registration: Participants can pre-register for the conference call here: Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
5/3/24 6:50:00 AM ET
$NBY
Biotechnology: Pharmaceutical Preparations
Health Care

Novabay Pharmaceuticals Announces Preliminary Net Revenue For The Second Quarter Of 2024 Of $2.4M Versus Consensus Of $3.15M And For The First Half Of 2024 Of $5M, Primarily Derived From The Company's Eyecare Products

Chat with this insight

Recent Analyst Ratings for
$NBY

$NBY
SEC Filings

SEC Form DEFA14A filed by NovaBay Pharmaceuticals Inc.

SEC Form DEFA14A filed by NovaBay Pharmaceuticals Inc.

SEC Form DEFA14A filed by NovaBay Pharmaceuticals Inc.

$NBY
Press Releases

Fastest customizable press release news feed in the world

Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand

NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results

NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price

$NBY
Financials

Live finance-specific insights

NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results

NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024

$NBY
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Garlikov Julie

SEC Form 4 filed by Freiman Paul E.

SEC Form 4 filed by Sit Swan

$NBY
Market Insights

Live Market Insights

Novabay Pharmaceuticals Announces Preliminary Net Revenue For The Second Quarter Of 2024 Of $2.4M Versus Consensus Of $3.15M And For The First Half Of 2024 Of $5M, Primarily Derived From The Company's Eyecare Products

NovaBay and Eyenovia Begin Co-Promotion of Eyecare Products to Ophthalmic Surgery Centers

NovaBay Pharmaceuticals Announces Warrant Exercise At Reduced Price Of $2.50; 90,381 Shares Exercised, Generating $225,952 In Gross Proceeds

$NBY
Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc.

SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

$NBY
Leadership Updates

Live Leadership Updates

Innovations in Disinfection Technology Aid the Return of Workers

Novabay Pharmaceuticals Announces Preliminary Net Revenue For The Second Quarter Of 2024 Of $2.4M Versus Consensus Of $3.15M And For The First Half Of 2024 Of $5M, Primarily Derived From The Company's Eyecare Products

Chat with this insight

Recent Analyst Ratings for $NBY

$NBY SEC Filings

SEC Form DEFA14A filed by NovaBay Pharmaceuticals Inc.

SEC Form DEFA14A filed by NovaBay Pharmaceuticals Inc.

SEC Form DEFA14A filed by NovaBay Pharmaceuticals Inc.

$NBY Press Releases

Fastest customizable press release news feed in the world

Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand

NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results

NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price

$NBY Financials

Live finance-specific insights

NovaBay Pharmaceuticals to Hold Second Quarter 2024 Conference Call on August 13, 2024

NovaBay Pharmaceuticals Reports First Quarter 2024 Financial Results

NovaBay Pharmaceuticals to Hold 2024 First Quarter Conference Call on May 9, 2024

$NBY Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Garlikov Julie

SEC Form 4 filed by Freiman Paul E.

SEC Form 4 filed by Sit Swan

$NBY Market Insights

Live Market Insights

Novabay Pharmaceuticals Announces Preliminary Net Revenue For The Second Quarter Of 2024 Of $2.4M Versus Consensus Of $3.15M And For The First Half Of 2024 Of $5M, Primarily Derived From The Company's Eyecare Products

NovaBay and Eyenovia Begin Co-Promotion of Eyecare Products to Ophthalmic Surgery Centers

NovaBay Pharmaceuticals Announces Warrant Exercise At Reduced Price Of $2.50; 90,381 Shares Exercised, Generating $225,952 In Gross Proceeds

$NBY Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc.

SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

SEC Form SC 13G/A filed by NovaBay Pharmaceuticals Inc. (Amendment)

$NBY Leadership Updates

Live Leadership Updates

Innovations in Disinfection Technology Aid the Return of Workers

Recent Analyst Ratings for
$NBY

$NBY
SEC Filings

$NBY
Press Releases

$NBY
Financials

$NBY
Insider Trading

$NBY
Market Insights

$NBY
Large Ownership Changes

$NBY
Leadership Updates